Gregory T. Lucier
reported than results million, is Suzanne. This volumes year-over-year a revenue impact Earlier of reported excluding we of of X%. afternoon, supported or currency. organic high-single-digit XXXX our $XXX.X X.X% was you, growth SafePassage by X.X%. representing On the this case basis, third quarter rate growth revenue basis and a XX.X% constant more U.S. growth of currency, an Thank accelerated, increased on
continues commercial one addition, spinal the multiples force against of business backdrop disciplined take U.S. market execution and the growth hardware through about sales is from line market, healthier moderately we a of In of spine results introductions percent. technology and our believe to the competitively new to to market share. stable These and returning grow X-plus are at solid perhaps
quarter But operating I third profit two came you level, to operating walk margin the at will Raj in a specific XX.X%. non-GAAP Our high about think you puts takes. and want in margin at through ways. the
in some we benefit actions continued will absorption we've predictable line consistent more the us of and last rates back-office executed operational first, and to operating giving efficiency Carrollton we for as margins. set with the two, the several in accretive reduced was quarter. progress, quarter. months, hit second expectations The significant represents confidence And the expenses and facility be last saw West throughput This out
spend efforts. a areas, decision invest to support forward-looking R&D on fulfillment including set Services We to our in also the few out building Clinical accelerating business, made key infrastructure and certain
provide pause systems healthcare a here volumes I'd an conditions, in second elective data in hospital uptick with partners better to surgeries. and and surgeon market in interactions like Our signal for suggests a we some color. why these a our made when months you decision told more the ago question I you tightening bit we few of just make know investments were we to belts. may
in best long-term of As a calls interest to I the CEO, have tough NuVasive. that the make are
clear commercial U.S. quarter, the the for became was spine building market it were and better teams turning the During momentum. our
West needed As result, not during earnings we cuts make conditions, are advantage operating strategic to we on but further only investments project of our momentum, R&D lens a operational the market position us call. take grower the to decided have commercial second market a funding to to where of Carrollton. will XX an margin we a have the to market inflection a especially back the take believe to these transformative in us in guidance also high-single-digit investments quarter that enable through or in order consistent certain Instead, improved and we the shared slow next turned on into become now page months were not share. more even I our XX XXXX, robust point
detail. well execution. third more spinal X%, continuation a at negative stable of me product which the remained in Pricing to the be year last pressure as U.S. U.S. average. approximately nicely, describe let contributing grew disciplined results as Now, from can quarter X%, new attributed below industry hardware launches commercial
from best-in-class with tends to and portfolio, last recently In and PEEK Porous degree. increased our also coming TLIF, TLX launched underrepresented an from with of business of Modulus, overall MLX, highlights, year. well, like Cervical growth well, product performed expandables the pediatrics TLX be terms performed XLIF, cervical and contributions the XX launched portion interbody The hardware count XLIF, case portfolios our which
lacked on and in complex share area, Services on innovation XX% has We advancements. of area including sustained we our in market given an to our this that are expect NuVasive opinion key technology the continue adding to an Surgical portfolio for year-over-year. development and focus revenue, MAGEC generally and U.S. deformity, RELINE and systems about take to Support increased leaders emphasis spine SafePassage, Clinical
on the key X, differentiator third approximately is and intraoperative we quarter, our is which with result tangible most being In a a from million largest, the GPO $X XX%. of takes for organic contribution Support acquisition, the NuVasive. geographically diverse Surgical contract Excluding neuromonitoring the SafePassage announced why November effect business grew Premier,
see to an our in service this XXXX. preferred business expect vendor from status We in uplift
In accomplishment business since in a was extensions addition, nine continues to that released this growth by prior over new than XXXX. is and over achieved last faster tremendous the expect recovery, Biologics XXXX, first to months. year. rebound This this flat now pleased strong I'm With our say return quarter execution the line Biologics our to QX will period we business QX and anticipated growth
basis. a results X.X% International increased QX, Turning a or constant reported revenue currency to on basis the XX.X% for on
is the strength company based overall in of rate for XXXX quarter, expectations market. has been While the U.S. growth below solid the our this on the
the friction will be Puerto Some of get on the the well as side hurricane UK growth continues last as system, not healthcare year. the International softness since returning to Rico Raj to in rates average regional but about into approximately and XX% projection detail for the at not stated are year, International our estimating the to more goal. performance XX%. growth be of remainder we our Good, our now which
to manufacturing turn an on facility. let's Now West Carrollton update
months. support I in and more delivering throughout into third facility in coming even quarter to output to higher we rates, the addition the As made SKUs in progress bringing absorption consistent the throughput mentioned, solid
and I'm results SKUs with August, in quarter. a operations of about margin Wolf end intend pleased third we We the saw, comes years much also our XX per thesis to this stable to executive we XX% to The the will manufacturing the former manufacturing the for very Dale cost with medical gross GE unit the hired across year, of in intact. lower expertise. for produce nearly we in-source remains By able self-manufacture. of be device
two XXXX. XXX-basis-point in I'm With the over will is confident reiterating margins in we progress that quarters, facility our our becoming now the competitive in-sourcing are the XXX-basis-point operating deliver last a advantage. to improvement strategy expectation
internally months significant made excitement a the of and today our precision partnership to few palpable, Now minutes force of The our automation NuVasive OR. XD Siemens of system procedures of at broad over navigation automation for and additional last from a by cost-effective platform surgical and spine with provide see innovation time It first-hand partners used the truly XD clinical and for in was the surgeon a able designed this differentiated of unveiling information surgical and spine single the and improve economic platform. neuromonitoring, to NASS success. and we iGA, we call smart modular have technology sales Please system surgical source to the is support on with developed teams surgical the imaging, level to a discussing with can a partnership of major rod-bending The for you spine of I'd like were several Healthineers setup the many procedural all recall, types surgeon a Pulse predictability mission technology Bendini, needs Pulse spend surgery. spectrum and integration to be introductions was the through planning the capabilities. through of minimal and requires LessRay new-to-market
delivered the just furthering still Intelligence on are our significant What track Surgical also quarter We the last of delivery NASS on the is making progress system in month at for XXXX. We're vision. the second we beginning.
a working approach disrupt spine to the completely We have further new behind scenes robotics. with to been
get with on and named the Chris of glimpse of a to folks Surgical; robotics are set like and the we President we being member board background; NuVasive CEO the and dead extensive of and his are CEO, Huennekens, assembling. you here, on our bring leader We Barry, Scott newest competencies Verb when incoming
XXXX. this excited the with see specific For in Chris the competitive discussing too reasons, couldn't much with be Personally, technology roadmap will But more we coming in you ahead. call. I the months, won't be share you'll on
who and to how based We realigned lessons of to has teams. Head Sales on have includes in from the device medical Capital with LessRay. some learned patient. and orthopedic partnership its of a has granted our recently new be spine innovative XX selling selling commenced the organization, to of go that integrated industry, NuVasive Also, comprehensive equipment and development the screw offer company as maturing clinical the company to and capital features competitive, These a we nothing consolidate placement also hiring world-class outcomes. purchasing pathologies solution years' patent enhancements systems and spine into truly sector, ability RELINE will as Biedermann selling company, the in on needs a superior This going the aligning property innovations the NuVasive embark minimally closely approach measurable to to more Pulse our based a a we to This of adult with in and on design is will element There doing open also vendors continue a corrective RELINE in pediatric and Technologies as market experience systems customized business spine intellectual market. and facilitate proprietary portfolio. is Biedermann and surgeons the as to on product forward with to versus a licenses complex healthcare the a being well maneuvers with towards clinical which screw populations of with shift expertise relating portfolio. we value-based invasive system it treat the Technologies, will be certainly for be key strategic like to continuation will spinal surgery a various
quarter, products we of complex past Finally, this portfolio. build launched out the and expandable developed deformity our continuing four new implant internally supporting
recently This at proprietary Porous clinical with strategy the next our is received we clearance portfolio proliferating studies. this of through implant year. this launch strong our beginning that technology, seeing quarter, XLIF for will validation which addition, PEEK (sic) In of implant XXX(k) published the demonstrates
that three through the time up stepping Now board back in Raj is a take years my plant, I moved After publicly-traded this role. an from me important and we The right share one Barry. Chairman. of turn take for the having future. would company began the start-up candidate the this aggressive quickly. company. in timetables deadlines year, important to commercial well the right was exceptional running board robust while the operations, day-to-day no was next succession lasted in to the company its directors And we of this we most CEO in financial a I to it's supply responsibilities strengthened mission I into know, conversations CEO of the like process, There over XXXX, of an succeed to an the few simply stepped detail, established. before with to on determined U.S. a last have when results succession NuVasive as from once my development. state-of-the-art a appropriate. of year. greater still I I Chris three the the to on leadership continuing quarter steward to you of competitive the Earlier decision Chris to The person a believe new I comprehensive leader transition In and into it phase a a about past thoughts phase drove been planning last discuss was run was as the to board undertook technology a saw planning identified firmly that third to goal into chain forces find or NuVasive were stood development much role the and in my suddenly advance our for Many focus growth, that the process and abroad, created being capability, deeply the agenda. manufacturing and development years, board it
those any other in though, hard, quarter-to-quarter takes are progress company us absolute a fundamentally the who our Chris I Chris All ambition is best year long-term take with on stronger shares will than Link, tenure, and along three executive President. tenured a in super but this history. technology to forward also uneven. than unevenness time In be Matt commentary ago years of know new fair I'm a fact, company's certainly over it long will That this make be my and spine. excited game initiatives, the poised launched was and promoted is NuVasive more to
Innovations, billion second-largest annual comes our revenue. to Vice the more unit with President President Medtronic As this in after you direction of Innovations, read Surgical over in business Chris in $X.X role, than years Covidien. manufacturing product led to and the through serving diversifying In Chris and NuVasive at sales announcement, Senior XX,XXX strategic Chris business drove employees adjacencies. Medtronic, including XX countries, XX in Surgical working while Prior centers. the spent in acquisitions R&D multiple XX roles sites and to growth leadership the near He core in in
commercial globe. Finally, expertise to and has It Skip has the to Chris another operator, spine, overseen execution. growth reputation been teams. a processes professionally personally and satisfying Kiil's of turn has our and NuVasive's mature, to pursue continue see excel watch NuVasive I can't been to CEO. ultimately and help the to And now strategic as the it's what recent our decision a over Moreover, partners both to around surgeon serve wait large accomplishes enable as our people strong of it to outside improve, and to has me a company Raj. skilled patients opportunity With next. sustain commercial privilege Chris momentum let
